06.16.25 -- Tariffs On Toys … And API? Biopharma As The Next Battleground

Our EMEA Advance Biotech Grant Program is open for European biotech startup companies to help them accelerate to clinic faster. Enter for a chance to win €148,400 in products & services here.

Explore how a contract manufacturer that is approved as a certified FTZ subzone can help sponsor companies unlock significant benefits and gain a competitive edge in the global pharmaceutical industry.

Needle innovations, including the usage of shorter needles with ultra-thin wall technology for prefilled syringes, support the delivery of drugs with greater volumes, which enhances the end-user experience.

Discover how robotic gloveless isolator sterile fill-finish systems (SFF) can accelerate early-phase drug development, ensuring enhanced sterility and streamlined processes for biopharma innovation.

Jumai Abioye, Pan Access Innovations, and Bikash Chatterjee, Pharmatech Associates, lay out for Outsourced Pharma readers the most common issues with IND submissions.

Antibody-drug conjugate (ADC) development requires tightly integrated manufacturing. Streamlined, end-to-end solutions reduce complexity, improve quality, and accelerate time-to-market.

As we balance the time-to-market and risk for novel therapies, we must anticipate changing needs for combination device development, highlighting the technological paradigm shift.

Learn how embracing advanced computational and human-relevant testing methods can transform your drug development process and accelerate your path to clinical success.

Examine the ways to design and de-risk molecules, streamlining the path to GMP manufacturing and clinical trials, and case studies that provide insight into key activities.

UHPLC-MS is now widely used in pharma, enabling efficient HCP identification and quantification through an implementation-based approach.

Ensure the integrity and performance of your mAb intermediate by adhering to strict storage and handling protocols that safeguard its critical attributes for successful conjugation.

Join KBI Biopharma for a webinar on transposase-enabled cell line development. Built on Selexis® SUREtechnology™ and CHO-M™, this platform delivers high titers, rapid development, and stability for complex biologics. Learn how it accelerates timelines, supports diverse molecule formats, and meets regulatory demands—offering a scalable, efficient alternative to traditional CLD methods. Perfect for teams seeking speed, quality, and flexibility in biotherapeutic development. Click here to learn more.

Streamline your entire change control process and simplify validation with MasterControl Change Control™ and our scalable validation solutions tailored for FDA-regulated environments.

In an increasingly competitive environment, working with the right CDMO is vital for successful drug lifecycle management. 

This presentation highlights how simplified execution with development, filling, and analytics under one roof ensures safe, efficacious products reach patients in need.

Establish productive, robust, scalable, and efficient cGMP processes more quickly and easily with the XS Technologies platform which offers a toolbox of system components.